Showcases Stock ranks

Kitov Pharamceut Ads (KTOV)
0.895  0.014 (1.55%) 08-05 16:00
Open: 0.915 Pre. Close: 0.8813
High: 0.9499 Low: 0.88
Volume: 15,483,172 Market Cap: 137M
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. The company operates through two segments, Pain and Hypertension; and Oncology. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is Consensi a combination of APIs celecoxib and amlodipine besylate. It is also developing NT219, a small molecule that targets two oncology-related proteins to overcome resistance to cancer drug treatment. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.95 - 0.953 0.953 - 0.956
Low: 0.871 - 0.875 0.875 - 0.879
Close: 0.884 - 0.889 0.889 - 0.894
Stock Technical Analysis
Target: Six months: 1.21
One year: 1.42
Support: Support1: 0.83
Support2: 0.70
Resistance: Resistance1: 1.04
Resistance2: 1.21
Pivot: 0.80
Moving Averages: MA(5): 0.84
MA(20): 0.80
MA(100): 0.54
MA(250): 0.66
MACD: MACD(12,26): 0.02
Signal(12,26,9): 0.02
%K %D: %K(14,3): 69.52
%D(3): 66.87
RSI: RSI(14): 60.09
52-Week: High: 1.44
Low: 0.22
Change(%): 19.7
Average Vol(K): 3-Month: 3186675
10-Days: 1256329
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.

KTOV has closed It is unclear right now based on current numbers. 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to KTOV's normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Thu, 02 Jul 2020
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update - GlobeNewswire

Thu, 25 Jun 2020
Kitov Closes $35.0 Million Registered Direct Offering Nasdaq:KTOV - GlobeNewswire

Tue, 23 Jun 2020
Kitov Announces $35.0 Million Registered Direct Offering Nasdaq:KTOV - GlobeNewswire

Fri, 22 May 2020
Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients - GlobeNewswire

Wed, 20 May 2020
Kitov Announces U.S. Commercial Launch of Consensiā„¢ - GlobeNewswire

Thu, 14 May 2020
Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program - GlobeNewswire

Financial Analysis
Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 158.04
Shares Float (M) 33.47
% Held by Insiders 4.67
% Held by Institutions 28.19
Shares Short (K) 4760
Shares Short Prior Month (K) 6750
Stock Financials
EPS -0.302
Book Value (p.s.) 0.530
Profit Margin
Operating Margin -680.00
Return on Assets (ttm) -28.9
Return on Equity (ttm) -53.9
Qtrly Rev. Growth
Gross Profit (p.s.) 0.006
Sales Per Share 0.006
EBITDA (p.s.) -0.043
Qtrly Earnings Growth
Operating Cash Flow (M) -5.58
Levered Free Cash Flow (M) -4.85
Stock Valuation
PE Ratio -2.96
PEG Ratio
Price to Book value 1.69
Price to Sales 141.45
Price to Cash Flow -25.35
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator